PRESS RELEASE published on 01/23/2026 at 07:00, 5 months 4 days ago BB Biotech: Preliminary full-year 2025 results and dividend proposal BB Biotech AG reports strong full-year 2025 results with +34.2% total return in CHF, +37.0% in EUR, and +53.7% in USD, proposes dividend of CHF 2.25 per share at AGM on March 19, 2026 Dividend Proposal Stock Market Full-year Results BB Biotech AG 2025 Performance
BRIEF published on 10/28/2025 at 13:20, 7 months 29 days ago BB Biotech surperforme avec de solides résultats au troisième trimestre 2025 Fusions Et Acquisitions BB Biotech T3 2025 Secteur Des Biotechnologies Indice NASDAQ Biotech
BRIEF published on 10/28/2025 at 13:20, 7 months 29 days ago BB Biotech Outperforms with Strong Q3 2025 Results Biotech Sector M&A BB Biotech Q3 2025 Nasdaq Biotech Index
PRESS RELEASE published on 10/28/2025 at 13:15, 7 months 29 days ago Edison issues report on BB Biotech (BION) Edison issues positive report on BB Biotech (BION) with strong Q325 results, outperforming its benchmark. Sector outlook remains favorable with M&A as key performance driver Edison M&A BB Biotech Outperforming Q325 Results
BRIEF published on 10/24/2025 at 07:05, 8 months 3 days ago BB Biotech AG Releases Interim Report Highlighting Significant Profit Increase Investment Company BB Biotech AG Interim Report Net Profit Increase Drug Developers
BRIEF published on 10/24/2025 at 07:05, 8 months 3 days ago BB Biotech AG publie un rapport intermédiaire soulignant une augmentation significative des bénéfices BB Biotech AG Société D'investissement Augmentation Du Bénéfice Net Rapport Intermédiaire Développeurs De Médicaments
BRIEF published on 10/24/2025 at 07:05, 8 months 3 days ago Surperformance de BB Biotech au troisième trimestre 2025 dans un contexte de reprise sectorielle BB Biotech Performances Du Troisième Trimestre 2025 Indice Nasdaq Biotechnology Thérapies À Base D'ARN Reprise Du Secteur
BRIEF published on 10/24/2025 at 07:05, 8 months 3 days ago BB Biotech's Q3 2025 Outperformance Amid Sector Recovery Sector Recovery BB Biotech Q3 2025 Performance Nasdaq Biotechnology Index RNA-based Therapeutics
PRESS RELEASE published on 10/24/2025 at 07:00, 8 months 3 days ago EQS-Adhoc: BB Biotech AG publishes its interim report BB Biotech AG publishes interim report for the first nine months of 2025, reporting CHF 106 mn net profit. More details at report.bbbiotech.ch/Q325 Financial Results Investment Company Net Profit BB Biotech AG Interim Report
PRESS RELEASE published on 10/24/2025 at 07:00, 8 months 3 days ago BB Biotech Q3 2025: Portfolio outperformance amid early signs of sector recovery BB Biotech AG reports strong Q3 2025 performance with portfolio outperforming Nasdaq Biotech Index, driven by solid net profit, key company milestones, and strategic investments BB Biotech AG Interim Report Sector Recovery Q3 2025 Portfolio Outperformance
Published on 06/27/2026 at 01:40, 8 hours 14 minutes ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 9 hours 54 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 10 hours 54 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 11 hours 4 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 11 hours 39 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/27/2026 at 00:05, 9 hours 49 minutes ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 9 hours 50 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 10 hours 18 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 10 hours 18 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 10 hours 27 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
